Edwards Lifesciences

Update in progress

EW (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Edwards Lifesciences provides products and technologies to treat advanced cardiovascular diseases worldwide. It offers transcatheter aortic valve replacement with the Edwards SAPIEN family, and transcatheter repair and replacement for mitral and tricuspid disease with PASCAL and EVOQUE. It also markets surgical structural heart solutions, including INSPIRIS RESILIA and related valve technologies (KONECT RESILIA, MITRIS RESILIA), and aortic valves. Distributed through direct sales and distributors; based in Irvine, California.

Company score

Sentiment: -0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.23; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.59; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -1.39; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.04; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.18; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive